About
Our research focuses on the health issues of blindness, cancer and drug abuse, which have huge socioeconomic implications.
Our lab applies engineering principles to advance our understanding of the interactions of therapeutic nanoparticle platforms with biological barriers and disease pathophysiology. This knowledge guides us to better design new biomaterials and nanotherapeutic-based treatments for eye disorders, cancer and other diseases.
Our research program operates at the interface of nanoengineering, materials science and translational medicine. We aim to translate technologies to have a meaningful impact on human health.
News
Congratulations to Ehsan Kaffash for starting his co-op in Bayer in January - May 2025.
Congratulations to Diane Ingabire for being awarded the NIH/NIDA F31 NRSA predoctoral fellowship on “Novel therapeutics for treating opioid use disorder."
Congratulations to Surendra Poudel and Ehsan Kaffash for winning the 2024 Joseph P. Schwartz Award from the VCU Department of Pharmaceutics.